Santorvastin Indications/Uses

SANTORVASTIN is indicated as an adjunct to diet for the reduction of elevated total-C, LDL-C, apo B, and TG in patients with primary hypercholesterolemia, combined (mixed) hyperlipidemia, and heterozygous and homozygous familial hypercholesterolemia when response to diet and other non pharmacological measure are inadequate.
Prevention of Cardiovascular Complication: In hypertensive patient (40 years or older) and dyslipidemia with at least 3 risk factors for future cardiovascular events such as LVH, ECG abnormalities, NIDDM, peripheral vascular disease, post history of cerebrovascular events including transient ischemic attack (TIA) ≥3 months previously, microalbuminuria/proteinuria, smoking (regular smoker within the last year of 20 cigarettes or cigars/week), TC/HDL-C ratio ≥6, and history of coronary artery disease event in a first degree relative before age 55 (males) or 60 (women), SANTORVASTIN is indicated to: Reduce the risk of fatal CHD and non-fatal MI; reduce the risk of stroke; reduce the risk of revascularization procedures and angina pectoris.
Pediatric Patients (10-17 years of age): SANTORVASTIN is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy, the following findings are present: a. LDL-C remains ≥190 mg/dL or; b. LDL-C remains ≥160 mg/dL and: There is a positive family history of premature CVD or two or more other CVD risk factors are present in the pediatric patient.